Mounjaro for sale

Name: Mounjaro for sale
SKU: 9239
Price: 165.00 USD
Availability: InStock

$165.00

Tirzepatide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. It lowers blood sugar by causing the release of your body’s natural insulin and decreasing the amount of sugar your liver makes.

Price $165 per box of pens

Category: Uncategorized

Description
Reviews (0)
Enquiry

Description

Mounjaro (tirzepatide) is an injectable medication that’s used with diet and exercise to treat type 2 diabetes in adults.

The use of Mounjaro has not been studied in patients who have had pancreatitis.

Mounjaro should not be used in patients with type 1 diabetes.

Fact Table
Formula	C225H348N48O68
License	US FDA
Bioavailability	80%
Legal status	Rx-Only
Chemical Name	Tirzepatide
Elimination half-life	Five days
Dosage (Strength)	–
Pregnancy	Insufficient data
Brands	Mounjaro
Protein binding	Albumin
PubChem CID	156588324
MedlinePlus	a622044
ChEBI	–
ATC code	–
DrugBank	DB15171
KEGG	D11360
Routes of administration	Subcutaneous

Directions

Mounjaro is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose injectable pens.

Follow the instructions that come with your Mounjaro prescription. Talk to your doctor or pharmacist about your questions or concerns.

Use Mounjaro as instructed by your doctor.

Mounjaro should be injected subcutaneously in the abdomen, thigh, or upper arm. Injection sites should be rotated with each dose.

Mounjaro dosage:

The recommended starting dose is to inject 2.5 mg subcutaneously once a week with or without food and increased to 5 mg subcutaneously once a week after 4 weeks of treatment. The dosage may be increased by 2.5 mg increments at 4-week intervals depending on medication response. The dose should not exceed 15 mg subcutaneously once a week.

Ingredients

Mounjaro contains tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist.

Contraindications

Do not use Mounjaro if you or your family has a history of a type of thyroid cancer known as medullary thyroid carcinoma or if you have Multiple Endocrine Neoplasia syndrome type 2.

Do not use Mounjaro if you are allergic to tirzepatide or any of the other ingredients or excipients contained in Mounjaro.

Cautions

WARNING: RISK OF THYROID C-CELL TUMORS

In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO.

WARNING: RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

Discuss your medications, allergies, medical problems, and pregnancy or breastfeeding status with your doctor before you begin treatment with Mounjaro.
Mounjaro may cause pancreatitis.
Mounjaro may cause low blood sugar if used with insulin or another type of medication that can lower blood sugar. Test your blood sugar levels and treat low blood sugar as your doctor has instructed.
Mounjaro may cause allergic reactions that can be severe. Get emergency care right away if you develop shortness of breath, swelling of your face, lips, tongue, or throat, rash, or rapid heart rate.
Mounjaro can cause acute kidney damage.
Mounjaro can cause gastrointestinal events that can be severe.
Mounjaro can cause acute gallbladder disease.
Patients who have had diabetic retinopathy should be monitored for complications or worsening of diabetic retinopathy.

Side Effects

The most common side effects experienced with Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain.

Call your doctor right away if you have side effects that bother you or won’t go away.